Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
17.7M
-
Number of holders
-
5
-
Total 13F shares, excl. options
-
407K
-
Shares change
-
+361K
-
Total reported value, excl. options
-
$618K
-
Value change
-
+$549K
-
Number of buys
-
4
-
Number of sells
-
-2
-
Price
-
$1.52
Significant Holders of Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) as of Q4 2024
6 filings reported holding KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share as of Q4 2024.
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 407K shares
of 17.7M outstanding shares and own 2.29% of the company stock.
Largest 6 shareholders include UMB Bank, n.a. (371K shares), Virtu Financial LLC (13.7K shares), CITADEL ADVISORS LLC (11K shares), UBS Group AG (10.8K shares), BANK OF AMERICA CORP /DE/ (13 shares), and HRT FINANCIAL LP (0 shares).
This table shows the top 5 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.